<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The supercritical antisolvent (SAS) technique is one of the most versatile [
 <xref rid="B35-pharmaceutics-11-00021" ref-type="bibr" class="xref">35</xref>] and widely researched techniques using supercritical CO
 <sub class="sub">2</sub> for micronization and microencapsulation [
 <xref rid="B10-pharmaceutics-11-00021" ref-type="bibr" class="xref">10</xref>,
 <xref rid="B35-pharmaceutics-11-00021" ref-type="bibr" class="xref">35</xref>,
 <xref rid="B36-pharmaceutics-11-00021" ref-type="bibr" class="xref">36</xref>,
 <xref rid="B37-pharmaceutics-11-00021" ref-type="bibr" class="xref">37</xref>,
 <xref rid="B38-pharmaceutics-11-00021" ref-type="bibr" class="xref">38</xref>,
 <xref rid="B39-pharmaceutics-11-00021" ref-type="bibr" class="xref">39</xref>,
 <xref rid="B40-pharmaceutics-11-00021" ref-type="bibr" class="xref">40</xref>,
 <xref rid="B41-pharmaceutics-11-00021" ref-type="bibr" class="xref">41</xref>,
 <xref rid="B42-pharmaceutics-11-00021" ref-type="bibr" class="xref">42</xref>,
 <xref rid="B43-pharmaceutics-11-00021" ref-type="bibr" class="xref">43</xref>,
 <xref rid="B44-pharmaceutics-11-00021" ref-type="bibr" class="xref">44</xref>,
 <xref rid="B45-pharmaceutics-11-00021" ref-type="bibr" class="xref">45</xref>,
 <xref rid="B46-pharmaceutics-11-00021" ref-type="bibr" class="xref">46</xref>,
 <xref rid="B47-pharmaceutics-11-00021" ref-type="bibr" class="xref">47</xref>,
 <xref rid="B48-pharmaceutics-11-00021" ref-type="bibr" class="xref">48</xref>,
 <xref rid="B49-pharmaceutics-11-00021" ref-type="bibr" class="xref">49</xref>,
 <xref rid="B50-pharmaceutics-11-00021" ref-type="bibr" class="xref">50</xref>,
 <xref rid="B51-pharmaceutics-11-00021" ref-type="bibr" class="xref">51</xref>,
 <xref rid="B52-pharmaceutics-11-00021" ref-type="bibr" class="xref">52</xref>]. The process can be applied to a wide range of compounds and biopolymers that have limited solubility in supercritical CO
 <sub class="sub">2</sub>. The SAS process has been applied in micronizing APIs, and has been shown to produce improve bioavailability and the solubility of hydrophobic drug compounds by size reduction and the control of crystal morphology [
 <xref rid="B41-pharmaceutics-11-00021" ref-type="bibr" class="xref">41</xref>]. Different biopolymeric morphologies (threads, sponges, and microparticles) can also be achieved from SAS processes [
 <xref rid="B49-pharmaceutics-11-00021" ref-type="bibr" class="xref">49</xref>]. Although the SAS is favorable for the production of formulations for hydrophobic drugs with low bioavailability and poor aqueous solubility [
 <xref rid="B41-pharmaceutics-11-00021" ref-type="bibr" class="xref">41</xref>,
 <xref rid="B44-pharmaceutics-11-00021" ref-type="bibr" class="xref">44</xref>,
 <xref rid="B47-pharmaceutics-11-00021" ref-type="bibr" class="xref">47</xref>,
 <xref rid="B53-pharmaceutics-11-00021" ref-type="bibr" class="xref">53</xref>], the encapsulation of hydrophilic compounds [
 <xref rid="B40-pharmaceutics-11-00021" ref-type="bibr" class="xref">40</xref>,
 <xref rid="B54-pharmaceutics-11-00021" ref-type="bibr" class="xref">54</xref>] have also been demonstrated by dispersing the hydrophilic drug in the organic solution. The co-precipitation produces monolithic matrix systems rather than reservoir systems, and the drug release profiles typically follow diffusion-controlled or polymer degradation mechanisms [
 <xref rid="B10-pharmaceutics-11-00021" ref-type="bibr" class="xref">10</xref>].
</p>
